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Abstract While treatment of keloids and hypertrophic scars normally shows modest results, we found that treat-
ment with bleomycin was more promising. The present study was divided into two parts. In the first part the
aim was to show the results using a combination of bleomycin and triamcinolone acetonide per cm2 (BTA). In the
second part the objective was to determine the response to both drugs in large keloids that were divided into 1
cm2 squares, treating each square with the dose previously used. In the first part of the study, the clinical response
of 37 keloids ranging from 0.3 to 1.8 cm2 treated with BTA were followed up over a period of 1- 2 years. 0.375 IU
bleomycin and 4 mg triamcinolone acetonide were injected every 3 months. In the second part of the study we
reviewed the clinical response in six patients with large keloids. The monthly dose administered never exceed-
ed 3 IU of bleomycin. The first study showed 36 keloids (97.29%) softening after the first dose. In the second
study, 5 showed different responses (the response was complete in the four smaller keloids). The largest keloid
needed 9 doses to achieve an improvement of 70%. In conclusion, combined treatment with 0.375 IU of
bleomycin and 4mg of triamcinolone acetonide to 1 cm2 was considered to be an acceptable procedure for the
treatment of keloids. The best results were obtained in keloids over 1 cm2 or when divided into 1 cm2 square
areas. Larger series need to be performed in order to confirm these results..
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Resumo Enquanto normalmente o tratamento de queloides e cicatrizes hipertróficas mostra resultados modera-
dos, o tratamento com bleomicina revelou resultados mais promissores. Este estudo foi dividido em duas partes.
Na primeira parte, o objetivo foi mostrar os resultados da utilização de uma combinação de bleomicina e aceto-
nido de triancinolona por cm2 (BAT). Na segunda parte, o objetivo foi determinar a resposta aos dois medicamen-
tos em queloides grandes, que foram divididos em quadrados de 1 cm2, tratando cada quadrado com a dose uti-
lizada anteriormente. Na primeira parte do estudo, a resposta clínica de 37 queloides de 0,3 to 1,8 cm2 tratados
com BAT foi monitorada por um período de 1 a 2 anos. Injeções de 0,375 UI de bleomicina e 4 mg de acetonido
de triancinolona foram aplicadas a cada 3 meses. Na segunda parte do estudo, revisamos a resposta clínica em 6
pacientes com queloides grandes. A dose mensal administrada nunca excedeu 3 UI de bleomicina. O primeiro
estudo mostrou que 36 queloides (97,29%) amoleceram após a primeira dose. No segundo estudo, 5 mostraram
diferentes respostas (a resposta foi completa nos quatro queloides menores). O queloide maior necessitou de 9
doses para apresentar melhora de 70%. Concluindo, o tratamento combinado com 0,375 UI de bleomicina e 4 mg
de acetonido de triancinolona por cm2foi considerado um procedimento aceitável para o tratamento de queloi-
des. Os melhores resultados foram obtidos em queloides com mais de 1 cm2 ou divididos em áreas de 1cm2.
Estudos mais amplos deveriam ser realizados, para confirmar esses resultados. 
Palavras-chave: Bleomicina; Queloide; Triancinolona acetonida
Received on 09.04.2012.
Approved by the Advisory Board and accepted for publication on 10.08.2012. 
* Study undertaken at the Deparment of Dermatology, Virgen Macarena University Hospital – Seville, Spain.
Financial Support: None
Conflict of Interest: None
1 Chief of Dermatology Department, Board Member of International League of Dermatology Societies - Head Professor of Dematology, Virgen Macarena
University Hospital – Seville, Spain. 
2 MD, Consultant Dermatologist - Department of Dermatology and Venereology Virgen Macarena University Hospital – Seville, Spain. 
3 MD, Consultant Traumatologist - General Surgical Department, Virgen Macarena University Hospital – Seville, Spain.
4 MD, Surgical Dermatology Fellowship - Department of Dermatology, Imbanaco Medical Center – Cali, Colombia. 
©2013 by Anais Brasileiros de Dermatologia
An Bras Dermatol. 2013;88(3):387-94.
388 Camacho-Martínez FM, Rodriguez-Rey E, Camacho-Serrano F, Wagner A
INTRODUCTION
Keloids are benign hyperproliferative growths
of dermal collagen usually resulting from excessive
tissue response to skin injury; they are characterized
by a tendency to recur. However, spontaneous keloids
can occur without previous skin trauma. Keloids
invade clinically normal adjacent skin and are often
painful or/and pruritic. 
Although their etiology is not fully understood,
it is well-known that the combination of high proli-
dase activity (up to four-fold compared to normal
skin) and the increase of type I procollagen and type I
collagen concentration in the tissue (especially the lat-
ter) are involved.1 There is hereditary or racial predis-
position. The condition affects the presternal area, ear
lobes, shoulders, ankles and/or face. 
Keloids may cause pain, movement limitation,
and other physical and psychological problems. The
search for an effective treatment is therefore essential.
Different options such as intralesional injections of
bleomycin or corticosteroids either alone or combined
with cryotherapy, compression therapy, silicone sheet-
ing, radiation therapy, laser therapy, 5-fluorouracil,
interferon, retinoids, imiquimod 5% cream,
tacrolimus, verapamil and botulin toxin have been
used, most of them with the aim of achieving   the best
functional and cosmetic solution possible.1-5
Bleomycin is a useful drug in dermatology for
intralesional therapy to treat cutaneous warts,
Bowen’s disease, basal and squamous cell carcinomas
and haemangiomas.6-11 Local side-effects include
hyperpigmentation, pain, necrosis, and atrophy.12
Different reports present bleomycin as an effective
treatment in keloid therapy and hypertrophic scars
using different application methods such as dermojet,
multiple needle punctures or syringe injection.2,12,13
However, the dose required per cm2 of surface
and the possibility of avoiding side- effects with sub-
sequent injections of triamcinolone acetonide has not
been investigated to date in large series.
The objective of the first study was to find the
ideal dose of bleomycin and triamcinolone acetonide
for each 1 cm2 of keloid. In the second study the aim
was to demonstrate the response of larger keloids
divided into 1 cm2 squares in order to inject into each
area the dose that had been previously demonstrated
as being more effective.
MATERIAL AND METHODS
Between May 2004 and May 2006 we treated 10
white patients, 4 males and 6 females, aged 19 – 39
years, with Fitzpatrick skin phototypes II, III and IV.
Two patients (nos. 8 and 9) presented one keloid; the
others had between 3 and 9.  38 keloids and 2 hyper-
trophic scars (patient no. 7) were included in our
study (Table 1). Three keloids bigger than 2 cm2
(patients nos. 1, 4, and 6) were considered in the sec-
ond study. In the first study 35 keloids of under 2 cm2
and two hypertrophic scars were treated.
The keloids were located on the back, shoul-
ders, presternal and scapular regions (Figures 1 - 6).
The hypertrophic scars were located in the right
abdominal wall and right thigh. Keloids were second-
Patient Sex Age Skin Etiology Location Lesion Previous
Type (size cm2) Treatment
1 M 19 III NODULOCYSTIC ACNE PRESTERNAL 6 (0.5-1.5) SURGERY
BACK 3 (1-1.8) LASER THERAPY
2 F 23 III SURGERY PRESTERNAL 2 (1.1/1.5) TRIAMCINOLONE ACETONIDE
SHOULDER L 2 (1.2/1.5) SILICONE 
3 F 27 II SPONTANEOUS PRESTERNAL 1(1.8) NO
SCAPULAR R/L 2 (1.0/1.5)
4 M 39 III NODULOCYSTIC ACNE PRESTERNAL 2 (1.0/1.3) TRIAMCINOLONE ACETONIDE
5 M 19 IV NODULOCYSTIC ACNE PRESTERNAL 4 (0.3-1.8) SILICONE 
6 M 27 III NODULOCYSTIC ACNE PRESTERNAL 4 (1.2-1.8) NO
7 F 20 II TRAUMATIC SCAR CHEST 2 (1.0/1.3) NO
ABDOMINAL WALL 1 (1.4) (Hypertrophic scar-HS) 
SHOULDER L 1 (1.5)
RIGHT THIGH 1 (1.4) (Hypertrophic scar-HS) 
8 F 28 III SPONTANEOUS PRESTERNAL 1 (1.2) SILICONE
9 F 26 III SURGERY PRESTERNAL 1 (1.5) TRIAMCINOLONE ACETONIDE
10 F 29 III TRAUMATIC SCAR SHOULDER L 1 (1.6) SILICONE
SCAPULAR R 3 (0.6-1.3)
TABLE 1: First Study Patients’ characteristics
L= Left R= Right
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FIGURE 1: Three keloids of 1.0 cm2, 1.2 cm2 and 1.8 cm2 right-to-left
on back, before (a) and after two sessions of treatment (b)
FIGURE 2: Two keloids of 1.2 cm2 and 1.5 cm2 on the left shoulder
in a woman before (a) and after two sessions of treatment (b).
Atrophy, most evident in the outer
FIGURE 3: Presternal keloid of 1.8 cm2 before (a) and after two ses-
sions of treatment (b), showing complete flattening
FIGURE 4: Keloid of 1.0 cm2 in right scapular region before (a) and
after two sessions of treatment (b), showing significant flattening 
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B
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We used the same method in all our patients. In
previous studies we had injected different doses from
0.25 to 0.50 ml (= 0.375 – 0.750 IU) for keloids of 1 cm2,
demonstrating that 0.25 ml was sufficinet enough to
obtain good results. In this present study we injected
0.25 ml (= 0.375 IU by cm²) into an area of 1 cm² -l 1.2
cm² and increased the dose by 0.05 ml for each addi-
tional 0.2 cm².14,15
In the second study we divided keloids into 1
cm² squared areas (patient nos. 1, 4 and 6)  and accept-
ed three new patients with large keloids (nos. 11, 12
and 13) (Figures 7 and 8) . The three latter were men
aged 19-35 years, all with phototypes III, and with
large keloids in the center of the chest as a result of
nodulocystic acne. The size of these six keloids was
20.46 cm2 (6.2 x 3.3 cm) in patient no. 1; 3.96 cm2 (2.2 x
ary to acne in 4 patients (nos. 1, 4, 5 and 6); to surgery
in two patients with lateral projection on the scars in
relation to the stitches (nos. 2 and 9); to traumatic scars
in two patients (nos. 7 and 10); and spontaneous or of
unknown origin in two patients (nos. 3 and 8). Only 3
patients (nos. 3, 6 and 7) had not been referred for pre-
vious therapies (Table 1). All the patients were
informed of the type of treatment and gave their writ-
ten consent. 
Exclusion criteria: patients under 18 years were
not considered suitable for this treatment; pregnant
and women likely to become pregnant women were
not enrolled in the study. Regarding the keloids and
hypertrophic scars, Patients being treated for  keloids
and hypertrophic scars during  the previous six
months were also excluded.
FIGURE 5: Four presternal keloids between 0.3 to 1.8 cm2 before (a)
and after two sessions of treatment (b). Excellent softening but dif-
ferent flattening from significant to complete in relation to size
FIGURE 6: Large keloids of 3.96 cm2 located on left shoulder, before
(a) and after three sessions of treatment (b). Complete flattening
FIGURE 7: Keloid on left shoulder of 1.5  cm2 before (a) and after three sessions of treatment (b). Excellent softening, high significant flatte-
ning and slight atrophy
A
B
A
B
A B
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FIGURE 8: Double presternal
keloid (a) divided into 24 and 8
squares up-and-down respective-
ly (b). Reduction of numbers of 1
cm² squared areas can be obser-
ved as result of treatment.  After
three sessions (nine subsessions
of 4 (b), 3 (c), and 2 (d) in which
maximum of 3.0 IU bleomycin
was injected in each, the result
showed excellent softening and
highly significant flattening (e,f)
TABLE 2: Patients’ characteristics (2nd Study)
L= Left R= Right
Patient Sex Age Skin Type Etiology Location Lesion Previous 
(size cm2) Treatment
1 M 19 III Nodulocystic acne Presternal 1 (6.2x3.3) Surgery
4 M 39 III Nodulocystic acne Shoulder L 1 (2.2x1.8) Triamcinolone acetonide
6 M 27 III Nodulocystic acne Presternal 1 (4.0x2.1) No
11 M 35 III Nodulocystic acne Presternal 1 (3.2x2.2) Triamcinolone acetonide
12 M 28 III Modulocystic acne Presternal 1 (4.1x2.3) No
13 M 31 III Nodulocystic acne Presternal 1 (8.2x3.3 + 4.1x2.0) No
1.8 cm), in patient no. 4; 8.40 cm2 (4.0 x 2.1 cm) in
patient no. 6; 7.04 cm2 (3.2 x 2.2 cm) in patient no. 11;
9.43 cm2 (4.1 x 2.3 cm) in patient no. 12; and 35.26 cm2
(8.2 x 3.3 cm + 4.1 x 2.0 cm) in patient no. 13 (Figure 8
and Table 2).
A concentration of 1.5 IU/ml of bleomycin dilu-
tion was prepared from 15 IU in 10 ml of physiologic
serum. The injection of bleomycin was slow – a rate of
0.05 ml per second. We never injected more than 3 IU
of bleomycin per session. For this reason the large
keloids received 3 IU for each 8 cm² with follow-up
subsessions every 6 weeks for patient nos. 6 and 12,
and monthly sessions for patients no.1 and 13.  The
latter patient received his total dose in four, three and
two subsessions over a total period of thirteen and a
half months as the size of keloid gradually reduced.
(Figure 8). In three cases only we injected 0.2 ml/cm²
(0.3 IU/cm²) in the first treatment, but this variant was
not taken into account in the study overall.
Subsequently, we infiltrated 4-5 mg/cm2 of a 40
mg/ml triamcinolone acetonide solution to obtain
whitening (0.10-0.125 ml in a syringe of 0.5 ml). We
never injected more than 5 mg/cm2 of triamcinolone
acetonide, nor a total dose of 30 mg per keloid. The
final step was to apply a silicone patch which had to
A
B
C
D
E
F
be kept in place for two days. The sessions were
repeated at 3 monthly intervals, with the exception of
the above-mentioned larger keloids. Treatment
response was evaluated in terms of flattening and
softening of the lesions.
Patients were followed up every three months
during 1- 2 years to observe recurrences and any side
effects. The same physician assessed all the patients
during their follow up (FMC), together with an exter-
nal assessor. 
Flattening was evaluated by comparing photos
of the keloid before and after treatment and by meas-
uring scar height (reduction percentage from base-
line), classified on a 5-point scale – “1” was minimal
flattening (< 50%); “2” moderate flattening (50-75%);
“3’ significant flattening (75-90%); and “4” highly sig-
nificant flattening (> 90%) and “5” complete flattening
(100%). Softening was evaluated according to a per-
sonal pliability scale by means of the “pinching tech-
nique”: level 1 signified impossible to pinch (bad
response); level 2 represented easy to pinch but with
permanent erythema (partial response); and level 3
was assessed by a pinch producing an effect similar to
normal skin (excellent response). We consider this
personal method easier to perform than the 4-point
scale commonly used in burn scars.16
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RESULTS
The response of each keloid in both studies (1
and 2) is indicated in table 3, numbered from 1 to 43.
From an aesthetic point of view all the patients
in the first study were satisfied with the final results,
although in our view the results obtained in the two
presternal keloids of patient No. 4 (keloid nos. 18 and
19) were not entirely satisfactory.
In 36 cases (97.29%), partial or complete soften-
ing (level 2-3) was obtained after the first session.
Complete flattening was achieved in 24 keloids
(64.86%) in the second session. Only in four keloids
(10.81%) were patients satisfied after the first session
(patient no. 1 – keloids nos. 5, 6, 7 (1-1,5 cm2) and
patient no. 9 – keloid no. 36 (size 1.5 cm2 ) all located
in the presternal area), and two keloids (5.40%) (no.
34, 39) required four  treatment sessions (see Figures 1,
2, 4 and 6). Five keloids (13.51%) (nos. 11, 12, 22, 28
and 40) achieved highly significant flattening,
although no. 40 called for four sessions; and six
(16.21%) (keloid nos. 15, 18, 19, 23, 24 and 37) showed
significant flattening (Figures 3, 5 and 6).
In the second study the six larger keloids,
divided into 1 cm² square areas (nos. 1, 20, 29, 41, 42
and 43), responded excellently after three sessions in
50% of the cases (nos. 20, 41 and 42), and partial soft-
ening after 4, 3 and 3 sessions in case nos. 1, 29 and 43
, although case 1 needed 12 subsessions, and case 43 a
total of 9 subsessions, the last one completed after
about 14 months of treatment (Figure 8 and Table 3).
Only one case (2.70%) achieved moderate flattening
(case 1). In this keloid measuring 20.46 cm2 (patient
no. 1), we performed surgery and laser therapy eight
months before the intralesional infiltrations with
bleomycin and triamcinolone acetonide. After twelve
doses and four subsessions of 3 IU in each 8 cm2 area,
the response was ‘moderate’ (Table 3). The other large
keloids (nos. 20, 29, 41, 42 and 43) were divided into 4,
9, 8, 10 and 32 quadrangular areas of 1 cm² (Figure
8.a,b). After 3 sessions on keloids 20, 29, 41 and 42 we
obtained a complete flattening, but keloid no. 43
required 9 subsessions (4, 3 and 2 times each session)
in order to obtain a ‘highly significant’ flattening, but
with atrophy (Figure 8).
Three lesions (nos.11, 12 and 15) recurred with-
in 3-12 months, and the treatment was repeated at a
follow-up session three months later. After 18-24
months of follow-up, keloids of the first study and
numbers 41 and 42 of the second study maintained
their softening and flattening, as well as normal skin
color, with the exception of no. 1 which maintained
erythema and telangiectasias.
Eight keloids in the first study (nos. 13, 14, 31,
32, 33, 34, 37, 39) presented atrophy. This was especial-
ly evident in no. 13.  All needed a twice-a-day applica-
PATIENT Nº SESSIONS RESULTS SE R
KELOIDS
1 S F U-A
1 4 (3)[12] 2 2 ● Δ **
2 2 3 5
3 2 3 5
4 2 3 5
5 1 3 5
6 1 3 5
7 1 3 5
8 2 3 5
9 2 3 5
10 2 3 5
2
11 2 3 4
12 2 3 4
13 2 3 5 +++ Δ 
14 2 3 5 ++ Δ
3
15 2 3 5
16 2 3 3
17 2 3 5
4
18 2 2 3
19 4 2 3
20 3 3 5
5
21 2 3 5
22 2 3 4
23 2 3 3
24 2 3 3
6
25 2 3 5
26 2 3 5
27 2 3 5
28 2 3 4
29 3 (2)[6] 2 5
7
30 2 3 5
31 2 3 5 + 
32 2 3 5 + 
33 2 3 5 ++
34 4 3 5 + 
8
35 2 3 5
9
36 1 3 5
10
37 3 3 3 +
38 3 3 5
39 4 3 5 +
40 4 3 4
11
41 3 3 5
12
42 3 (2)[6] 3 5
13
43 3 (4-3-2)[9] + 2 4 ●
TABLE 3: First Study Patients’ characteristics
S= softening, F= flattening, SE= side effects, + = atrophy, ● = ulce-
ration, R = recurrence (Δ), Fig= Figure, **= loss of follow-up.
(n): sub-session/doses each session. [n]: Total sub-sessions
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tion of minoxidil 5% (Figure 2). Only lesion no. 13 dis-
played slight atrophy after 24 months of follow-up. 
The large keloids of cases 1 and 43 developed
necrosis of the central quadrants, followed by an ulcer
and subsequenly by an atrophic scar covered with
telangiectasias. As a result, case 1 was lost to follow-
up. 
Although both infiltrations are painful, none of
the patients complained of pain or severe pigmenta-
tion changes in the days after the infiltration. When
we compared the incidence of pain after injection of
bleomycin without the subsequent injection of 4
mg/cm2 triamcinolone acetonide, previously received
by several patients, all the patients reported that the
pain felt during several days after injection did not
occur when we applied the triamcinolone immediate-
ly post-injection.
COMMENTS 
Bleomycin is a cytotoxic polypeptide with anti-
tumoral, antibacterial and antiviral properties isolated
from the fungus Streptomyces verticillus. It is used as a
systemic chemotherapeutical agent since its mode of
action appears to inhibit DNA synthesis and DNA
destruction. RNA and protein synthesis is also inhib-
ited to a lesser extent.7,13 The active effect of bleomycin
used in the treatment of keloids and hypertrophic
scars  may possibly be explained by the inhibition of
collagen synthesis by human dermal fibroblasts or
stimulated by the presence of TGF-β.1, a cytokine
detected in scar tissues at high levels.17 Other action
mechanisms of bleomycin on keloids might be the
increase of fibroblast apoptosis or the reduction of the
lysyl oxidase levels, an enzyme found in high concen-
trations in keloids and hypertrophic scars.18,19
Previous studies have demonstrated that
intralesional injections of bleomycin in keloids and
hypertrophic scars is a well-tolerated treatment, with
few local and systemic side- effects, which suggests
that this treatment can be used as first line therapy for
keloids.12
In our experience, intralesional bleomycin is
painful, especially when dermojet injected, and partic-
ularly when treating plantar warts, where the pain is
extreme and unavoidable, occasionally requiring
anesthetics.20
On the other hand, the treatment of keloids
with triamcinolone acetonide (TA) is a well-known,
long-term standard therapy that has been employed
as a single therapeutical procedure immediately after
surgery, with a reduction from 50% to 91.90% of the
possibility of a recurrence of keloids and of 50% to
95.24% in the case of hypertrophic scars, within 5
weeks after surgery.21-23 Unlike the anti-inflammatory
effect of corticosteroids, the effect of TA is to induce a
specific protein involved in the System A amino acid
transport in human keloid fibroblasts that reduces the
production of collagen and inhibits alpha.2-
macroglobulin, which in turn inhibits collagenase.24,25
The injection must always be performed in the papil-
lary dermis, where collagenase is produced, and not
in the subcutaneous tissue, given that it may produce
underlying fat atrophy.25 As for the pain caused by
injecting triamcinolone acetonide, when we injected
triamcinolone acetonide as the single therapeutic
agent, this was certainly painful for the patient, as it
was with bleomycin. For treating keloids, a number of
authors have proposed injecting a dose of 10 mg/ml
of TA at 3-6 ml/hour intervals, using an electric
syringe and pumping 40 times, 22 times with lido-
caine and 18 times without it.26 Hoigne’s effect was
reported after intra-keloid injection of triamcinolone
acetonide and lidocaine.27 Other authors used EMLA
or L-M-Y- (previously known as EMLA-Max) two
hours before the procedure.25 Finally, the combined
use of TA with cryotherapy seems to be better than
other combinations such as 5-fluorouracil or 585 nm
flash lamp-pumped pulsed-dye laser, or at least com-
parable.3,28,29 We did not employ radiation therapy as
proposed by other authors.25,30 Regarding the suitable
dose to be injected per cm², we found only one report
proposing 1-10 mg of TA, depending on the size of the
lesion, to be applied at four-week intervals.31 Other
side effects of TA frequently include hypopigmenta-
tion, which remains for between six and twelve
months.25
When we injected triamcinolone acetonide
immediately after bleomycin, pain was reduced in
minutes or even seconds, suggesting that this combi-
nation could well beneficial, at least hypothetically.
In the course of our study the greatest difficul-
ty was to correctly determine the exact quantity of
bleomycin and triamcinolone to be injected, as well as
deciding on the most suitable size of surface for such
doses. Our previous experiences with triamcinolone
acetonide after cryotherapy taught us which dose was
best able to reduce the pain caused by inflammation
after cryotherapy, although it had previously caused
minimal side effects.3
With respect to the bleomycin dose, although
Tanigaki and Endo applied 0.4 ml/cm² (=0.60 IU/cm²)
following a local anesthetic (2% prilocaine hydrochlo-
ride) - probably needed because they had used the
dermojet (not our current practice), we prefer to apply
0.375 IU using insulin syringes to inject the bleomycin
while slowly withdrawing the 1-cm-long needle.10
While is no significant difference between the quanti-
ty injected by the above authors (0.60 IU) and our rec-
ommendation (0.375 IU), we believe that it is simpler
to inject 0.25 ml with insulin syringes of 0.5 ml or 1 ml.
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The maximum volume per session was 2 ml (3 IU),
sufficient to treat 8 keloids of 1 cm² or 8 quadrants in
large keloids.
In conclusion, we consider that 0.375 IU of
bleomycin for each 1 cm2 is an effective and safe treat-
ment regardless of the technique employed. When
used in combination with 4mg triamcinolone ace-
tonide for each 1 cm2, side effects such as necrosis and
especially pain do not appear to be substantial,
although this combination may increase the risk of
dermal atrophy. We believe that our results were the
best obtained so far,  and this is the reason why we
started using the technique routinely in our depart-
ment for  all patients presenting for treatment of
keloids. However, we do believe that it is important to
undertake other comparative studies in order to con-
firm the significance of the results we obtained. ❑
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